CSL Limited

CSL

AU000000CSL8

Pharmaceuticals

Delayed Australian S.E. Other stock markets 02:10:52 2024-04-24 am EDT			5-day change	1st Jan Change
278.4 ^AUD	-0.19%		+2.14%	-2.86%

Apr. 24	CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy	CI
Apr. 24	Australian shares climb on banks, energy boost; March-quarter CPI in focus	RE

CSL Limited Reports Earnings Results for the Half Year Ended December 31, 2021

February 15, 2022 at 04:09 pm EST

CSL Limited reported earnings results for the half year ended December 31, 2021. For the half year, the company reported sales was USD 5,807.8 million compared to USD 5,596.1 million a year ago. Revenue was USD 6,041.2 million compared to USD 5,739.4 million a year ago.

Net income was USD 1,760.3 million compared to USD 1,810 million a year ago. Basic earnings per share from continuing operations was USD 3.85 compared to USD 3.98 a year ago. Diluted earnings per share from continuing operations was USD 3.84 compared to USD 3.97 a year ago.

Latest news about CSL Limited

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy	Apr. 24	CI
Australian shares climb on banks, energy boost; March-quarter CPI in focus	Apr. 23	RE
Australian shares follow Wall Street higher, miners limit gains	Apr. 22	RE
Australian shares rebound as miners and financials jump; inflation data awaited	Apr. 21	RE
Vifor Pharma offers to rectify anti-competitive behaviour against rival	Apr. 19	RE
Miners boost Australian shares; NZ cenbank keeps rates steady	Apr. 10	RE
New Zealand shares hold gains as c.bank expectedly holds rate; Aussie shares up	Apr. 09	RE
Australian shares rise on mining and healthcare boost; US CPI data, RBNZ in focus	Apr. 09	RE
Australian shares end higher as miners surge; US CPI in focus	Apr. 09	RE
Australian shares fall as financials and healthcare stocks drag	Apr. 02	RE
Australian shares hit record high; RBA cautious on inflation	Apr. 01	RE
Australian shares inch higher; inflation data reinforces subdued rate-cut view	Mar. 26	RE
CSL Prices $1.25 Billion Corporate Bonds Offering	Mar. 26	MT
Miners, healthcare firms push Australia stocks higher	Mar. 25	RE
Australian shares fall as miners, banks weigh	Mar. 10	RE
Banks drive Australian shares to record high on firming rate-cut bets	Mar. 08	RE
CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee	Mar. 06	CI
Morgan Stanley Adjusts CSL’s Price Target to AU$310 From AU$318, Keeps at Overweight	Mar. 05	MT
Australia Health Stocks to Remain at Premium to ASX200, Morgan Stanley Says	Mar. 05	MT
Australian shares skid off record highs to end lower; GDP data awaited	Mar. 04	RE
Australian shares end marginally up as energy, financials offset weak miners	Feb. 27	RE
Australian shares inch lower as banks offset commodity gains	Feb. 21	RE
Jarden Research CSL’s Price Target to AU$296.02 From AU$298.57, Keeps at Overweight	Feb. 13	MT
Australian shares end slightly lower; US inflation data on tap	Feb. 13	RE
Jarden Research Adjusts CSL’s Price Target to AU$298.57 From AU$316.16, Keeps at Overweight	Feb. 12	MT

Chart CSL Limited

Duration

Period

More charts

Company Profile

CSL Limited is an Australia-based biotechnology company. The Companyâs areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Companyâs segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q4 2024 Earnings Release

Related indices

S&P/ASX 200

More about the company

Income Statement Evolution

More financial data

Ratings for CSL Limited

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

180.7 USD

Average target price

199.4 USD

Spread / Average Target

+10.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-2.86%	87.37B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	41.01B
BIOGEN INC.	-21.94%	28.08B
UCB	+53.11%	24.72B
BIOMARIN PHARMACEUTICAL INC.	-5.41%	17.47B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.23%	11.69B
INCYTE CORPORATION	-17.60%	11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.96%	11.56B
SWEDISH ORPHAN BIOVITRUM AB	-0.22%	8.44B
INTRA-CELLULAR THERAPIES, INC.	+2.09%	7.72B

Biopharmaceuticals

CSL Limited

Equities

CSL

AU000000CSL8

Pharmaceuticals

CSL Limited Reports Earnings Results for the Half Year Ended December 31, 2021

EPS Revisions